1. CD25 expression is associated with unfavorable clinical outcome.
CD25 expression is associated with unfavorable clinical outcome. A, BCR–ABL1-positive B-ALL (n = 113, median OS, 1.0 years; 95% CI, 0.8–1.2) have a worse OS than the BCR–ABL1-negative B-ALLs (n = 352, median OS, 2.4 years; 95% CI, 1.8–3.8) in the E2993 cases (P < , log-rank test). B, CD25 positivity further stratifies BCR–ABL1-positive B-ALLs into 2 groups with significantly different clinical outcome: CD25-positive patients have significantly inferior OS (n = 69, median OS, 0.8 years; 95% CI, 0.6–1.1) than the CD25-negative patients (n = 44, median OS, 1.3 years; 95% CI, 0.9–2.5; P = , log-rank test). C, the CD25-negative BCR–ABL1-positive patients (n = 44) did not have significantly different OS than the BCR–ABL1-negative CD25-negative patients (n = 334, P = 0.08, log-rank test).
Huimin Geng et al. Cancer Discovery 2012;2:
©2012 by American Association for Cancer Research